Eli Lilly and Company measures and tracks its comprehensive value-chain greenhouse gas emissions across all fifteen standard categories mandated by corporate carbon accounting protocols, covering upstream and downstream activities such as purchased goods, logistics, and product lifecycle impacts. The pharmaceutical giant established a target to achieve 100% full value-chain emissions reporting transparency, aligning its broader sustainability strategy with science-based targets to minimize environmental footprints across its extensive global supplier and manufacturing networks.